142 related articles for article (PubMed ID: 2453751)
1. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.
Cambier P; van de Werf F; Larsen GR; Collen D
J Cardiovasc Pharmacol; 1988 Apr; 11(4):468-72. PubMed ID: 2453751
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.
Collen D; Stassen JM; Larsen G
Blood; 1988 Jan; 71(1):216-9. PubMed ID: 3120823
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model.
Wu Z; Van de Werf F; Stassen T; Mattsson C; Pohl G; Collen D
J Cardiovasc Pharmacol; 1990 Aug; 16(2):197-203. PubMed ID: 1697374
[TBL] [Abstract][Full Text] [Related]
4. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
[TBL] [Abstract][Full Text] [Related]
5. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog.
Kopia GA; Kopaciewicz LJ; Fong KL; Crysler CS; Boyle K; Ruffolo RR
J Cardiovasc Pharmacol; 1988 Sep; 12(3):308-16. PubMed ID: 2464103
[TBL] [Abstract][Full Text] [Related]
7. Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity.
Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Yui Y; Kawai C
J Cardiovasc Pharmacol; 1993 Dec; 22(6):834-40. PubMed ID: 7509901
[TBL] [Abstract][Full Text] [Related]
8. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
[TBL] [Abstract][Full Text] [Related]
9. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat.
Larsen GR; Metzger M; Henson K; Blue Y; Horgan P
Blood; 1989 May; 73(7):1842-50. PubMed ID: 2496774
[TBL] [Abstract][Full Text] [Related]
11. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
Van de Werf F; Jang IK; Collen D
J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin (Clexane, Lovenox), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability.
Mestre M; Uzan A; Sedivy P; Cavero I
Thromb Res; 1992 May; 66(2-3):191-206. PubMed ID: 1329253
[TBL] [Abstract][Full Text] [Related]
13. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
Longridge DJ; Follenfant MJ; Ford AJ
Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
[TBL] [Abstract][Full Text] [Related]
14. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
[TBL] [Abstract][Full Text] [Related]
15. Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator.
Hansen L; Blue Y; Barone K; Collen D; Larsen GR
J Biol Chem; 1988 Oct; 263(30):15713-9. PubMed ID: 3139674
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
Martin U; Sponer G; Strein K
J Am Coll Cardiol; 1992 Feb; 19(2):433-40. PubMed ID: 1732372
[TBL] [Abstract][Full Text] [Related]
17. Thrombolytic effects of a novel modified tissue plasminogen activator, E6010, on coronary thrombosis in the pig.
Adachi H; Nagaoka N; Nomoto K; Yuzuriha T; Shoji T
Jpn J Pharmacol; 1992 Mar; 58(3):309-19. PubMed ID: 1513078
[TBL] [Abstract][Full Text] [Related]
18. Newer thrombolytic agents.
Verstraete M
Ann Acad Med Singap; 1999 May; 28(3):424-33. PubMed ID: 10575530
[TBL] [Abstract][Full Text] [Related]
19. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.
Jackson CV; Crowe VG; Craft TJ; Sundboom JL; Grinnell BW; Bobbitt JL; Burck PJ; Quay JF; Smith GF
Circulation; 1990 Sep; 82(3):930-40. PubMed ID: 2118431
[TBL] [Abstract][Full Text] [Related]
20. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase.
Larsen GR; Timony GA; Horgan PG; Barone KM; Henson KS; Angus LB; Stoudemire JB
J Biol Chem; 1991 May; 266(13):8156-61. PubMed ID: 1708773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
